Q1 FY27 results analysis · August 07, 2026

Poly Medicure Ltd (POLYMED) Q1 FY27 Results Analysis: PAT Falls 8.4%, Employee Expenses Surge 70.6%

−8.4%PAT year on year, Rs. 85.27 Cr
Cofacto ResearchPublished August 07, 20262 min readNeutral read
Quick summary

Poly Medicure Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 525.38 Cr (+30.30% YoY) and PAT growth of -8.40% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 07, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 525.38 Cr (+30.30% YoY)
PAT (Q1)Rs. 85.27 Cr (-8.40% YoY)
EBITDA margin24.11%
EPS (Q1)Rs. 8.49 (-7.62% YoY)
Market capRs. 17,172.79 Cr
CMPRs. 1,693.80

Quarter Snapshot

Standalone margins improved and met guidance, but consolidated PAT declined 8.4% due to acquisition cost layers and a 70.6% surge in employee expenses. The credit outlook upgrade to Positive is a positive signal, but acquisition integration and cost control remain key watch items.

Key Investment Insights

Key Positives

  • Standalone EBITDA margin improved 154 bps YoY to 28.03%, at the upper end of the 25-27% guidance band
  • Consolidated revenue grew 30.3% YoY to Rs.525.38 Cr
  • Consolidated EBITDA margin recovered 3.1 ppt QoQ to 24.11%, within the 23-25% guidance band
  • CRISIL rating outlook revised to Positive from Stable

Risk Factors

  • Consolidated PAT declined 8.4% YoY to Rs.85.27 Cr despite 30% revenue growth
  • Employee benefits expense surged 70.6% YoY on a consolidated basis
  • Subsidiary EBITDA margin of ~6.2% is well below the group average, causing margin dilution

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.